Referanser:1. Hammarlund CS, Westergren A, Åström I, Edberg AK, Hagell P. The impact of living with Parkinson’s disease: balancing within a web of needs and demands. Park Dis. 2018. 2. Subramanian I, Farahnik J, Mischley LK. Synergy of pandemics: social isolation is associated with worsened Parkinson severity and quality of life. NPJ Parkinsons Dis. 2020;6:28. 3. Soleimani MA, Negarandeh R, Bastani F, Greysen R. Disrupted social connectedness in people with Parkinson’s disease. Br J Community Nurs. 2014;19:136-141. 4. Ahn S, Springer K, Gibson JS. Social withdrawal in Parkinson’s disease: a scoping review. Geriatr Nurs. 2022;48:258-268.5. American Parkinson Disease Association. Anxiety in Parkinson’s disease. Available from: https://www.apdaparkinson.org/article/anxiety-parkinsons-disease/. Accessed 2025 May. 6. Rastgardani T, Armstrong MJ, Gagliardi AR, Grabovsky A, Marras C. Communication about OFF periods in Parkinson’s disease: a survey of physicians, patients, and carepartners. Front Neurol. 2019;10:982. 7. Abeynayake I, Tanner CM. The economic impact of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 Suppl):S265-S269. 8. Rajagopalan K, Barton J, Pike J. Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: a neurologist/patient real world assessment in the US [abstract]. Mov Disord. 2018;33(suppl 2). 9. Thach A, Sutphin J, Coulter J, Mansfield C. Patient experiences and preferences for specific on-demand treatments for Parkinson’s disease-related “OFF” episodes [abstract]. J Manag Care Spec Pharm. 2020;26:S40. 10. Thach A, Sutphin J, Coulter J, Leach C, Pappert E, Mansfield C. Patient preferences for treating “OFF” episodes in Parkinson’s disease: a discrete choice experiment. Patient Prefer Adherence. 2021;15:1187-1196. 11. Soleimani MA, Negarandeh R, Bastani F, Greysen R. Disrupted social connectedness in people with Parkinson’s disease. Br J Community Nurs. 2014;19:136-141. 12. LeWitt PA, Hauser RA, Pahwa R, et al; SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-154. 13. Isaacson SH, Pagan FL, Lew MF, Pahwa R. Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161.